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ABSTRACT
Theophylline is a bronchodilator that also has an
anti-inflammatory effect. In Japan, methylxanthines,
including theophylline and aminophylline (theophyl-
line ethylenediamine), have been used widely in the
treatment of asthma. In some asthma management
guidelines, although methylxanthines are recommend
for the treatment of asthma, they are not preferred
primarily because of potential serious adverse effects
in case of overdose. The present review examines the
efficacy and adverse effects of sustained-release theo-
phylline and injectable methylxanthines in the treat-
ment of chronic asthma and acute exacerbation of
asthma by evaluating reports of published clinical
trials and a prospective survey on the occurrence of
serious adverse drug reactions to these agents. A pro-
spective survey on the safety of methylxanthines was
administered to adult patients (15–64 years of age),
mainly with asthma, in medical centers by physicians
certified as specialists by the Japanese Society of
Allergology. Review of published clinical trials has
shown that methylxanthines are effective in controlling
asthma. In the prospective study, in the case of
sustained-release theophylline, 3921subjects reported
by 66 medical centers and meeting the criteria for
inclusion in the survey were selected for analysis. In the
case of intravenous methylxanthines, 682 subjects
reported by 55 medical centers conforming and
meeting the criteria for inclusion in the survey were
selected for analysis. None of these subjects exhibited
serious adverse drug reaction with sustained-release
theophylline or intravenous methylxanthines. In
conclusion, methylxanthines are effective for the treat-
ment of asthma and are safe as long as the dose
administered accords with the protocols recom-
mended by asthma management guidelines.
Key words: adverse effects, asthma, efficacy, methyl-
xanthines, theophylline.
INTRODUCTION
Methylxanthines include theophylline and aminophylline,
an ethylenediamine derivative of theophylline, and they
have been used widely for the treatment of asthma.
Sustained-release theophylline is given orally to control
chronic asthma, whereas injectable methylxanthines,
including aminophylline and an injectable preparation
of theophylline, are given for the treatment of acute
exacerbations of asthma. In the past decade, many
national and international guidelines for the manage-
ment of asthma have been published and have recom-
mended the use of theophylline.1–7 However, some of
the guidelines recommend theophylline as an additional
bronchodilator for patients with asthma that remains
difficult to control after institution of moderate- to high-
dose inhaled corticosteroids. Theophylline is not preferred
primarily because of possible serious adverse effects that
may appear in case of theophylline overdose. Similarly,
for acute exacerbation, intravenous aminophylline is
recommended for use only in patients who fail to exhibit
improvement of severe bronchoconstriction following
repeated inhalation of β2-adrenergic receptor agonists
and administration of intravenous corticosteroids and
who are admitted to hospital or emergency care,
because overdosing with intravenous aminophylline may
cause serious adverse effects.1,3,4
The Japanese Guideline for Diagnosis and Treatment
of Asthma published in 1993 by the Japanese Society of
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Allergology (JGL1993),5 the Asthma Prevention and
Management Guidelines published in 1998 by a study
group supported by the Japanese Ministry of Health and
Welfare (JGL1998)6 and the Evidence-Based Asthma
Management Guidlelines published in 2002 by a study
group supported by Ministry of Health and Welfare (EBM-
JGL)7 have all indicated that sustained-release theophyl-
line can be given as an initial drug for mild to severe
persistent asthma alone or with low- to high-dose inhaled
corticosteroids and/or other anti-asthma agents. These
guidelines also note that intravenous methylxanthines
can be given in the early stage of moderate to severe
acute exacerbation of asthma as the first-line drug with
inhaled β2-adrenergic receptor agonists, subcutaneous
epinephrine and/or intravenous corticosteroids.5–7 The
present review examines the efficacy of methylxanthines
in the management of chronic asthma and the acute
exacerbation of asthma, as well as the adverse effects
of this agent. Recent prospective surveys on the safety of
methylxanthines in the treatment of asthma will be
described.
EFFECTS OF THEOPHYLLINE
Asthma is characterized clinically by reversible constric-
tion of the airway, induced mainly by spasm of the
bronchial smooth muscle, as well as by inflammation of
the bronchial wall with infiltration of inflammatory cells,
including eosinophils, T cells and mast cells associated
with airway hyperresponsiveness and airway remodel-
ing.8 Theophylline is a bronchodilator that also has
extrapulmonary effects, including anti-inflammatory
effects. The bronchodilator effect of theophylline may be
related to phosphodiesterase inhibition and is observed
at high concentrations (> 10 µg/mL theophylline),
whereas the anti-inflammatory effect is observed at
lower concentrations (5–10 µg/mL theophylline).9–13
EFFICACY AND ADVERSE EFFECTS OF 
SUSTAINED-RELEASE THEOPHYLLINE IN THE 
TREATMENT OF CHRONIC ASTHMA IN ADULTS
Clinical trials have shown that sustained-release
theophylline is effective in controlling the symptoms of
asthma and maintaining pulmonary function. No cases
of serious adverse effects have been reported in these
clinical trials, although sustained-release theophylline
has been reported to produce mild to moderate adverse
effects.9,11,14–18
The efficacy of sustained-release theophylline was
assessed by reviewing the following reports of clinical
trials. Clinical trials were subdivided in terms of the
type of approach, such as: (i) comparison with inhaled
corticosteroids; (ii) comparison of low-dose inhaled
corticosteroids plus sustained release theophylline and
high-dose inhaled corticosteroids; (iii) add-on effects of
sustained release theophylline to high-dose inhaled
corticosteroids; and (iv) effects of theophylline withdrawal
on asthma symptoms and inflammatory cell regulation.
Comparison with inhaled corticosteroids
Reed et al. compared sustained-release theophylline
with inhaled corticosteroid spray as the primary treat-
ment for chronic mild-to-moderate asthma in a double-
blind, double-placebo, randomized controlled trial of
1 year duration.14 They found that both treatments
were effective in achieving control of asthma and were
accompanied by anticipated adverse effects. Patients
with mild-to-moderate asthma received either beclo-
methasone dipropionate (BDP) spray (84 µg four times
per day) or sustained-release theophylline twice per day
in doses adjusted for optimal control of asthma. In this
trial, the dose of sustained-release theophylline was
adjusted by a blinded study investigator to establish and
maintain optimal control of asthma symptoms with
minimal adverse effects. To provide guidance and to
protect patients from theophylline overdose, an unblinded
investigator interpreted theophylline blood levels using a
steady state theophylline blood level of 8–15 µg/mL at
approximately 12 h after a dose as the target.
Both sustained-release theophylline and inhaled corti-
costeroid reduced symptoms promptly and achieved low
absenteeism from work or school and low rates of emer-
gency treatment for asthma. Inhaled BDP was slightly but
significantly more effective in reducing symptoms and the
use of supplementary bronchodilators. With regard to
adverse effects, there were no life-threatening adverse
reactions attributable to the medications investigated in
the study. There were no incidents of seizure, gastro-
intestinal bleeding or paroxysmal tachycardia. More
patients taking theophylline had headaches, insomnia,
tremor, nervousness and dizziness, presumably because
of its effects on the central nervous system and skeletal
muscle, and more also had gastric irritation, dyspepsia,
nausea and vomiting. More patients taking BDP had
oropharyngeal candidiasis, disturbance of the voice,
hoarseness and acute pharyngitis. The mean morning
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cortisol levels were similar in the two groups at the begin-
ning of the study, but by 6 and 12 months, cortisol levels
were lower in the group treated with BDP inhalation both
before and after cosyntropin injection. Review of individ-
ual case records disclosed no instance of a morning
cortisol level below 5 µg/mL that could be attributed to
BDP treatment. This trial showed that sustained-release
theophylline effectively controlled symptoms at a steady
state theophylline blood level of 8–15 µg/mL without
serious adverse effects.14
Comparison of low-dose inhaled 
corticosteroids plus sustained-release 
theophylline and high-dose inhaled 
corticosteroids
Evans et al.15 undertook a double-blind, placebo-
controlled trial for comparison of low-dose inhaled
budesonide (400 µg twice daily) plus theophylline (250/
375 mg twice daily) and high-dose inhaled budesonide
(800 µg twice daily) for moderate asthma. Both treat-
ments resulted in improvements of pulmonary function
that were sustained throughout the study. Treatment with
low-dose budesonide plus theophylline resulted in
greater improvements of forced expiratory volume in 1s
(FEV1). The median concentration of theophylline was
8.7 µg/mL. Concerning adverse effects, both treatments
were well tolerated. Nine of 31 patients who received
low-dose budesonide plus theophylline reported adverse
effects, including gastrointestinal upset, palpitations,
sore throat and headache, as did seven of 31 patients
who received high-dose budesonide (sore throat, gastro-
intestinal upset, rosacea and palpitations). No serious
adverse effects were reported in this trial. This trial
showed that for patients with moderate asthma and
persistent symptoms, low-dose inhaled budesonide plus
theophylline and high-dose inhaled budesonide yielded
similar benefits.15
Ukena et al.16 undertook a double-blind, placebo-
controlled trial for comparison of low-dose inhaled BDP
(200 µg twice daily) plus theophylline (250 mg twice
daily) and high-dose inhaled BDP (400 µg twice daily) for
patients with asthma who were not controlled with BDP
400 µg/day or an equivalent dose of another cortico-
steroid for 6 weeks. The mean serum theophylline
concentration was 10.1 µg/mL in the theophylline group.
The FEV1 and peak expiratory flow (PEF) at week 6 were
significantly increased in both groups. There were signifi-
cant improvements in asthma symptoms and the use of
rescue medication. There were no significant differences
in these parameters between the treatment groups.
With regard to adverse effects, both treatments were
well tolerated. No serious adverse events were reported.
Twenty-seven adverse events, which were either
pharmacologically predictable or attributable to asthma,
were observed in the BDP plus theophylline group
(gastrointestinal upset, palpitations and respiratory symp-
toms, such as dyspnea or cough), whereas 17 events
were reported for the BDP 800 µg group (gastrointestinal
upset, palpitations and respiratory symptoms). This study
demonstrated clinical equivalence of BDP 400 µg/day
plus theophylline and BDP 800 µg/day in patients with
asthma who were not controlled with BDP 400 µg/day or
an equivalent dose of other corticosteroids. The combi-
nation of low-dose inhaled steroid plus theophylline is a
suitable treatment for moderate asthma.16
Lim et al.17 undertook a randomized, double-blind,
parallel-group study comparing three treatments in
patients with symptomatic asthma who were on 400 µg
BDP daily and an inhaled β2-adrenergic receptor agonist
as required. The treatments examined were as follows:
(i) continuing low-dose inhaled corticosteroids alone
(BDP 200 µg twice daily); (ii) low-dose inhaled cortico-
steroids (BDP 200 µg twice daily) and low-dose theophyl-
line (sustained-release theophylline 200 mg twice daily);
and (iii) high-dose inhaled corticosteroid (BDP 500 µg
twice daily). These medications were given over a
6 month period. There were no overall differences in
PEF, diurnal variation or symptom score among the three
treatment groups, whereas the greatest within-group
improvement in evening PEF was found after the addition
of theophylline. No serious adverse effects were reported.
There were no significant differences among the treat-
ment groups in any commonly reported adverse effects.
In this study, although there was no significant difference
among the three treatments in terms of efficacy, the find-
ings suggested that the addition of low-dose theophylline
may be beneficial in patients whose asthma is not con-
trolled optimally on low-dose inhaled corticosteroid.17
Add-on effects of theophylline to high-dose 
inhaled corticosteroids
Rivington et al.18 undertook a double-blind, placebo-
controlled cross-over study on the effects on pulmonary
function of adding sustained-release theophylline
(400–600 mg once daily, adjusted to optimal serum
concentration), inhaled salbutamol (200 µg four times
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per day) and their combination or placebo for 14 days
in patients with moderately severe chronic asthma main-
tained on moderately high doses of inhaled cortico-
steroids (BDP; mean dose 1100 µg/day). Morning PEF
and FEV1 were significantly higher with sustained-release
theophylline alone or with the combination of sustained-
release theophylline and salbutamol than with salbuta-
mol alone or placebo. Evening PEF was higher with
sustained-release theophylline than with placebo.
Evening PEF was higher in the combination group than
in the salbutamol alone and placebo groups. No serious
adverse effects were reported. Adverse effects reported
were mild to moderate in severity and the mean severity
ratings for adverse effects reported by patients on the
daily diary cards did not differ among treatment groups.
This trial demonstrated that the addition of sustained-
release theophylline alone or its combination with
salbutamol each significantly improved pulmonary
function and asthma symptoms in patients treated with
high doses of inhaled corticosteroids and as-needed
β2-adrenergic receptor agonists.18
Effects of theophylline withdrawal on asthma 
symptoms and inflammatory cell regulation
Kidney et al.11 examined the effect of theophylline
withdrawal under placebo control in asthma patients
treated with long-term theophylline who were also
treated with high-dose inhaled corticosteroids. Theo-
phylline withdrawal was associated with a significant
increase in asthma symptoms, particularly at night, and
decreases in spirometric measurements and morning
PEF. These were accompanied by a significant fall in
the  number of peripheral blood monocytes (CD14+),
activated CD4+ T lymphocytes (CD4+/CD25+) and
activated CD8+ T cells (CD8+/HLA-DR+) in patients
with plasma theophylline > 5 µg/mL. Bronchial biopsy
revealed mirror image findings of those for peripheral
blood with increases in CD4+ and CD8+ lymphocytes in
the airway. No serious adverse effects were reported.
These observations of theophylline withdrawal suggest
that chronic treatment with theophylline, even at low
plasma concentrations, controls asthma symptoms,
improves pulmonary function and suppresses activated
T lymphocyte populations in the blood and decreases
the infiltration of these cells in the airway, showing that
theophylline has immunoregulatory effects that may be
useful in asthma therapy.11
Minoguchi et al.9 examined the effect of theophylline
withdrawal for 6 weeks in asthmatic patients whose PEF
was more than 80% of the predicted value on treatment
with both a moderate dose of inhaled dose corticosteroids
(BDP; 400–800 µg/day) and low-dose theophylline
(400 mg/day) for more than 3 months. Half the patients
were withdrawn at random from theophylline. With-
drawal of theophylline caused a significant increase in
asthma symptoms, a significant decrease in PEF and a
significant increase in the percentage of total and acti-
vated eosinophils in the sputum. No adverse effects were
described that were attributable to theophylline adminis-
tration. This trial suggests that long-term treatment with
low-dose theophylline has anti-inflammatory effects. The
additional use of theophylline with inhaled corticosteroids
appears to provide an effective treatment for moderate
asthma.9
Summary of the efficacy and adverse effects of 
sustained-release theophylline
Sustained-release theophylline has been shown to be
effective in controlling asthma symptoms and improving
pulmonary function. Theophylline, at low doses, is effec-
tive for asthma control. Theophylline can be used in
patients with milder disease and as an add-on therapy to
low to high doses of inhaled corticosteroids when further
asthma control is needed.9,11–18 No serious adverse effects
have been reported in these studies. Gastrointestinal
symptoms, including nausea, loss of appetite and vomit-
ing, were the most common early events. As long as
the target serum concentration was 5–15 µg/mL, as in
the studies cited, adverse effects were mild in severity.
EFFICACY AND ADVERSE EFFECTS OF 
INTRAVENOUS METHYLXANTHINES ON ACUTE 
EXACERBATION OF ASTHMA IN ADULTS
Clinical trails have shown that intravenous methylxan-
thines are effective in controlling the acute exacerbation
of asthma. In clinical trials in which serum concentra-
tions were controlled, no cases of serious adverse effects
were reported.
The efficacy of intravenous methylxanthines was
assessed by reviewing the following reports of clinical
trials. Clinical trials were subdivided in terms of the type
of approach as follows: (i) effects of intravenous methylxan-
thines compared with placebo; (ii) dose–response effects
of intravenous aminophylline; (iii) decreases in hospital
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admission rate by intravenous aminophylline; (iv) less
additional treatment of intravenous aminophylline
required compared with placebo and add-on effects to
inhaled β2-adrenergic receptor agonist; and (v) a newly
developed intravenous theophylline preparation for acute
exacerbation of asthma.
Add-on effects of intravenous aminophylline 
to inhaled β2-adrenergic receptor agonists and 
intravenous corticosteroids compared with 
placebo
Montserrat et al.19 treated patients hospitalized because
of exacerbation of asthma with intravenous aminophyl-
line or placebo in addition to standard treatment with
inhaled salbutamol and intravenous corticosteroids in
a randomized, double-blind, placebo-controlled study.
In the aminophylline-treated group, the mean (± SD)
plasma level of theophylline increased to 15.2 ±
3.6 µg/mL and forced vital capacity (FVC) and FEV1
increased by 16 ± 10 and 17 ± 12%, respectively. The
increase in pulmonary functions in the aminophylline-
treated group was significantly higher than in the
placebo-treated group. No significant changes in arte-
rial oxygen tension or ventilation–perfusion distribution
were found, whereas in placebo-treated patients moder-
ate worsening of ventilation–perfusion relationships
developed. No adverse drug reactions (ADR) were
described for intravenous aminophylline. This trial
demonstrated that, when given at therapeutic plasma
levels in severe exacerbation of asthma, intravenous
aminophylline moderately increased airflow rates without
disturbing pulmonary gas exchange.19
Huang et al.20 examined the effects of adding
intravenous aminophylline to nebulization of albuterol
(2.5–5 mg every 0.5–4 h) and intravenous methyl-
prednisolone (60 mg every 6 h) in adults hospitalized for
acute exacerbation of asthma in a randomized, placebo-
controllled double-blind study. Individualized dose of
aminophylline or placebo were given for 48 h. The
improvement in FEV1 at 3 and 48 h of admission in
the aminophylline-treated group was greater than in the
placebo-treated group (P = 0.023 and 0.048, respec-
tively). The aminophylline-treated group required less
nebulization of albutelol. There was no statistically signif-
icant difference in adverse effects. This study shows that
an individualized dose of intravenous aminophylline
added to frequent nebulization of albutelol and intra-
venous methylprednisolone appears to benefit adults
admitted to hospital with acute exacerbation of asthma
and that it is well tolerated when serum concentrations
are maintained within the therapeutic range.20
Dose–response effects of intravenous 
aminophylline
Mitenko and Ogilvie21 examined the physiological
responses to intravenously administered aminophylline
in nine hospitalized patients with asthma and examined
the relationship between pulmonary function and drug
administration. Continuous improvement of FVC and
FEV1 was observed over the plasma theophylline con-
centration range of 5–20 µg/mL. Improvement varied
directly with the logarithm of plasma theophylline
concentration. With regard to adverse effects, three
of nine patients experienced tachycardia with rates of
100–120 b.p.m. at the highest concentration of theo-
phylline (up to 24.6 µg/mL). Only one of these three
patients experienced nausea. Her maximal plasma theo-
phylline concentration was 24.62 µg/mL. No serious
adverse effects were reported. In this study, a dose–
response relationship was observed for theophylline
over  the plasma concentration range 5–20 µg/mL.
The authors suggested that intravenous theophylline is
safe and acceptable for the treatment of asthma within
this plasma theophylline concentration range.21
Decreases in hospital admission rate by 
intravenous aminophylline
Wrenn et al.22 undertook a randomized, double-blind,
placebo-controlled intervention study to assess the role
of aminophylline in the treatment of acute exacerbation
of asthma or chronic obstructive pulmonary disease
(COPD) when used in addition to the inhaled β2-
adrenergic receptor agonist metaproterenol and intra-
venous methylprednisolone. There was a threefold
decrease in hospital admission rate for patients treated
with aminophylline (6%) compared with those who
received placebo (21%; P = 0.016). Concerning adverse
effects, there was no difference in the frequency of
adverse effects, except for a trend towards a higher
frequency of nausea in the aminophylline group. This
trial suggested that aminophylline at a dose just below
the commonly accepted therapeutic range appeared to
decrease the rate of hospital admission of patients with
exacerbation of asthma or COPD.22
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Less additional treatment with intravenous 
aminophylline required compared with 
placebo and add-on effects to inhaled 
β2-adrenergic receptor agonists
Ohta et al.23 treated acute exacerbation of asthma with
intravenous aminophylline or inhaled salbutamol as the
initial treatment for the first hour. In the aminophylline-
treated group, the dose of aminophylline was designed
to yield a serum concentration of theophylline between
15 and 20 µg/mL within the first hour. The salbutamol-
treated group received four puffs (400 µg salbutamol)
delivered via a metered-dose inhaler every 15 min for
the first hour. One hour after initiation of treatment, the
effectiveness of the treatment was assessed. If the initial
treatment did not relieve exacerbation of asthma within
the first hour, the opposite treatment regimen was
administered additionally. Most patients seen in the
emergency clinic had already received inhaled short-
acting β2-adrenergic receptor agonists in both the
aminophylline and salbutamol treatment groups. Only
six of 34 patients (18%) who received intravenous
aminophylline first needed additional treatment with
inhaled salbutamol 1 h after initiation of treatment to
control exacerbation of asthma, whereas 17 of 19
patients in the salbutamol group (89%) needed addi-
tional treatment with intravenous aminophylline. Intra-
venous aminophylline exhibited add-on effects to
repeated inhalation of salbutamol. Concerning adverse
effects, no adverse reactions were reported in either
group. This study showed that intravenous aminophylline
could be as beneficial as salbutamol given by metered-
dose inhaler for acute exacerbation of asthma.23
A newly developed intravenous theophylline 
preparation for the treatment of acute 
exacerbation of asthma
Inoue et al.24 examined the effects of a newly developed
intravenous theophylline preparation in 16 asthmatic
patients with mild acute exacerbation. They administered
200 mg theophylline with 200 mL saline over 2 h. After
intravenous theophylline, PEF and FEV1 increased sig-
nificantly and asthma symptoms improved significantly.
As for adverse effects, none of the recipients had any
adverse effects. This trial showed that the newly devel-
oped intravenous theophylline preparation was effective
in controlling the acute exacerbation of asthma and
exhibited no adverse effects.24
Summary of the efficacy and adverse effects of 
intravenous methylxanthines
The studies described above and other controlled clini-
cal studies have shown that intravenous aminophylline/
theophylline has bronchodilor effects and is effective
for the treatment of exacerbation of asthma.19–31 In the
EBM-JGL, 22 studies were cited as scientifically valu-
able in determining the clinical usefulness of intravenous
aminophylline.7 In all studies except one, the loading
dose was 5.6–6.0 mg/kg bodyweight and the mainte-
nance dose was 0.6–0.9 mg/kg bodyweight. Fifteen of
22 studies found that aminophylline alone was effective
in improving acute exacerbation of asthma. Seven
studies found that intravenous aminophylline was effec-
tive in combination with other agents. Two studies
reported that intravenous aminophylline did not exhibit
add-on effects to treatments given beforehand.32,33
Three studies did not support the use of intravenous
aminophylline because it did not improve asthma
exacerbation and adverse effects, such as headache,
were frequent.34 In randomized clinical studies, amino-
phylline exhibited add-on effects to salbutamol or
epinephrine.22,24,25 One double-blind study showed that
intravenous aminophylline decreased the percentage
of hospital admissions compared with placebo (6 vs
21%).22 In one study of pregnant patients who were kept
on high doses of corticosteroids, intravenous aminophyl-
line did not shorten hospital admission.34
No serious adverse effects of intravenous aminophyl-
line administered for the treatment of acute exacerbation
of asthma were reported in the studies cited in the present
review. In most studies, there were no differences in less
serious adverse effects between intravenous aminophyl-
line and controls, although nausea appeared to be more
frequent in aminophylline-treated groups.
Together, these findings indicate that intravenous
aminophylline and theophylline are effective in treating
asthma exacerbation and are safe as long as the doses
used are within the therapeutic range.
PROSPECTIVE SURVEY OF THE SAFETY OF 
METHYLXANTHINES IN THE LONG-TERM 
CONTROL OF ASTHMA AND TREATMENT OF 
ACUTE EXACERBATION35,36
In Japan, methylxanthines have been used widely for
the long-term control of chronic asthma and also for the
treatment of acute attacks of asthma, as recommended
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in the Asthma Prevention and Management Guide-
lines.5–7,37 In contrast, some international guidelines and
national guidelines of other countries recommend the
use of sustained-release theophylline for chronic asthma
and also recommend intravenous aminophylline for the
treatment of severe exacerbation of asthma, but these
drugs were recommended as an alternative therapy or
not preferred principally because of potential serious
ADR.1,2,4
With this background, a subcommittee of the Asthma
Prevention and Management Guideline Committee in
Japanese Society of Allergology (JSA) conducted a survey
of the safety of theophylline and aminophylline products
in the treatment of asthma and COPD.35,36
The purpose of this survey was to search for serious
ADR to sustained-release theophylline and intravenous
methylxanthines (theophylline and aminophylline) in
adult patients (15–64 years of age) with asthma or
COPD. Serious ADR was defined as any untoward
medical occurrence that, at any dose: (i) results in death
or is life threatening; (ii) requires hospitalization or pro-
longation of hospitalization; (iii) results in persistent or
significant disability/incapacity; (iv) results in a congenital
anomaly/birth defect; and (v) does not meet any of the
above criteria for serious ADR, but may jeopardize
patients/subjects or may require medical or surgical
intervention to prevent one of the outcomes listed above.
In medical centers with physicians certified as special-
ists by the JSA, patients were registered to survey for
a arbitrary 1 month period between 1 September and
31 December 2001. In the case of use of sustained-
release theophylline, investigations were performed for
1 month after registration and in the case of the use of
intravenous methylxanthines, investigations were per-
formed during the infusion and for 6 h after infusion.
The following items were investigated in the survey:
sex/age, date of registration, reason for administration
(diagnosis), route of administration, dose and term of
administration, drugs administered other than methylxan-
thines and ADR and their severity.
For sustained-release theophylline, 3921 subjects
were selected for analysis among 4983 subjects reported
by 66 medical centers meeting the criteria for inclusion in
the survey. Of the subjects, 93.3% were patients with
asthma, 5.2% were patients with COPD and 1.5% were
patients with both asthma and COPD. For intravenous
methylxanthines, 682 subjects were selected for analysis
among 876 subjects reported by 55 medical centers
meeting the criteria for inclusion in the survey. Of these
subjects, 98.7% had asthma and the remaining patients
had COPD.
Doses of sustained-release theophylline and 
intravenous methylxanthines
Sustained-release theophylline 300–400 mg/day was
administered to 61.5% of patients. Of 610 subjects
who received intravenous aminophylline, 41.0% received
125 mg/day aminophylline and 43.2% received 250 mg/
day aminophylline. Of 77 subjects who received intra-
venous theophylline, 88.3% received 200 mg/day
theophylline.
Occurrence of serious ADR
No serious ADR were observed, not only in subjects
selected for analysis, but also in subjects not selected for
analysis because they did not meet the inclusion criteria.
Occurrence of non-serious ADR
With sustained-release theophylline, non-serious ADR
were observed in 54 of 3909 subjects (1.38%), includ-
ing tremor, insomnia, hypertonia, nausea, dyspepsia,
abdominal distension and palpitations. With intravenous
methylxanthines, non-serious ADR were observed in two
of 682 subjects (0.29%), including palpitations, nausea,
vomiting, tachycardia, flushing, headache, tinnitus and
perspiration. With sustained-release theophylline, the
incidence of ADR was not significantly related to
the  dose of the drug administered during the survey
period and diseases for which the drug was used.
Neither age nor sex was related to the incidence of ADR.
Among the patients receiving sustained-release theo-
phylline, the incidence of ADR was high for those with no
previous treatment with sustained-release theophylline.
The incidence pf ADR was high for patients who received
concomitant therapy with macrolides, but was not
related to the use of corticosteroids and β2-adrenergic
receptor agonists.
Conclusions
Methylxanthines, including theophylline and aminophyl-
line, are safe agents for the treatment of asthma and
COPD as long as they are used properly.
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EFFICACY AND ADVERSE EFFECTS OF 
SUSTAINED-RELEASE THEOPHYLLINE IN THE 
TREATMENT OF CHILDHOOD ASTHMA
In Japanese guidelines, sustained-release theophylline
is recommended for the control of persistent childhood
asthma and can be given alone or in combination with
other controllers, although in GINA 2002 the role of
methylxanthines in long-term treatment in childhood
asthma is limited.2,6,7,38 Because the anti-asthma effects
of theophylline can be detected even at a concentration
of 5 µg/mL and adverse effects are observed more
frequently at concentrations above 20 µg/mL, the
recommended therapeutic concentration ragne for
theophylline is 5–15 µg/mL.2,7,38,39
Three randomized clinical trials on sustained-
release theophylline will be discussed from 15 reports
cited in the section regarding childhood asthma in the
EMB-JGL.7
As a comparison of effects of sustained-release theo-
phylline to those of oral β2-adrenergic receptor agonists
in childhood asthma, Nishima et al. undertook a random-
ized, double-blind, placebo-controlled study on child-
hood asthma patients (6–12 years of age) comparing
sustained-release theophylline (200–600 mg/day) and
trimetoquinol (1–3 mg/day).40 Sustained-release theo-
phylline yielded significantly higher improvement of asthma
symptoms and pulmonary functions than the oral β2-
adrenergic receptor agonists. No serious adverse effects
were reported in either group. Milder adverse effects
were more frequent in the sustained-release theophylline
group. This study showed that sustained-release theo-
phylline was effective for chronic childhood asthma and
without serious adverse effects.40
As a comparison of the effects of sustained-release
theophylline with those of inhaled disodium cromogly-
cate in childhood asthma, Hambleton et al.41 performed
a randomized, double-blind, placebo-controlled cross-
over study of patients with childhood asthma (6–16 years
of age) using sustained-release theophylline, cromogly-
cate and their combination. No significant difference in
pulmonary function was noted among the three treatment
groups. The percentage of symptom-free days was higher
in the theophylline and combination groups than in the
cromoglycate group. No serious adverse effects were
reported in any of the three treatment groups. The inci-
dence of adverse effects did not differ between the three
treatment groups. This study showed that sustained-
release theophylline was effective in the treatment of
chronic childhood asthma without any serious adverse
effects.41
As a comparison of sustained-release theophylline
with inhaled corticosteroids in children with asthma,
Tinkelman et al.42 undertook a double-blind, placebo-
controlled trial for the comparison of inhaled BDP (84 µg
four times a day) and sustained-release theophylline
administered twice daily in doses adjusted for optimal
control of symptoms in children aged between 6 and
16 years with mild-to-moderate asthma. Both aerosolized
BDP and sustained-release theophylline were effective
primary treatments for mild-to-moderate chronic asthma
in children. There were no life-threatening adverse events
attributable to study medications reported. There were no
spontaneous reports of seizures, coma, gastrointestinal
bleeding or paroxysmal tachycardia. Other adverse
effects were observed significantly more frequently with
theophylline than with BDP. Growth velocity suppression
was noted with BDP. This study shows that both theophyl-
line and BDP are effective for the treatment of mild-to-
moderate asthma in children. The dose of sustained-
release theophylline should be determined following
recommended protocols and repeated measurement of
serum levels of theophylline is recommended.42
Summary of the efficacy and adverse effects of 
sustained-release theophylline in childhood 
asthma
Sustained-release theophylline alone or in combination
with other anti-asthma agents is recommended for the
treatment of children with mild-to-severe persistent
asthma. The dose of theophylline should be determined
following recommended protocols and repeated measure-
ment of serum levels of theophylline is recommended,
because there may be serious adverse effects with
overdosing.1,2,6,7
EFFICACY AND ADVERSE EFFECTS OF 
INTRAVENOUS METHYLXANTHINES IN THE 
TREATMENT OF ACUTE EXACERBATION IN 
CHILDHOOD ASTHMA
According to asthma management guidelines of Japan,
intravenous methylxanthines can be given as bolus
injections or drip infusions to treat acute exacerbation of
asthma that is greater than of moderate severity.6,7,38 In
contrast, in the section of hospital-based management
of exacerbation of childhood asthma in GINA 2002,2
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intravenous methylxanthines are recommended for con-
sideration only as an alternative therapy for the treat-
ment of acute exacerbation of asthma because of their
increased numbers of adverse effects. Moreover, there
are reports that intravenous aminophylline does not
exhibit add-on effects in children with severe asthma who
are already being treated with inhaled β2-adrenergic
receptor agonists and intravenous corticosteroids.43,44
No serious adverse effects have been reported in studies
in which serum levels were controlled within the recom-
mended range. A high level of serum theophylline was
associated with neurological or cardiovascular adverse
effects.45 Because the metabolism of methylxanthines
varies widely in children depending on age, medications
and the presence of fever and/or viral infection, the dose
of intravenous methylxanthines should be determined
following recommended protocols and repeated measure-
ment of serum levels of theophylline is recommended.2,38
Summary of the efficacy and safety of 
intravenous aminophylline in the treatment of 
acute exacerbation in childhood asthma
Taken together, the available information indicates that
intravenous methylxanthines can be given as bolus
injections or drip infusions to treat acute exacerbation
of childhood asthma of more than moderate severity.
Intravenous methylxanthines are safe as long as their
dose is determined following recommended protocols.
Repeated measurement of serum levels of theophylline is
recommended.
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